Skip to main content
MeiraGTx Holdings plc logo

MeiraGTx Holdings plc — Investor Relations & Filings

Ticker · MGTX ISIN · KYG596651029 LEI · 54930007YV6NYIOGFZ57 US Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2025-07-23 Regulatory Filings
Country KY Cayman Islands
Listing US MGTX

About MeiraGTx Holdings plc

https://meiragtx.com/

MeiraGTx Holdings plc is a clinical-stage genetic medicine company developing therapies for both rare and prevalent diseases. The company's primary focus areas include disorders of the eye, salivary gland, and central nervous system. MeiraGTx utilizes a proprietary riboswitch gene regulation platform designed to provide precise spatial and temporal control of gene expression. As a vertically integrated entity, it possesses end-to-end capabilities, including its own cGMP manufacturing facilities, to support a broad pipeline of therapeutic candidates. The company has multiple programs in clinical development, with several in late-stage trials.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-07-23 English
Director's Dealing 2025
Director's Dealing
2025-07-09 English
Regulatory Filings 2025
Regulatory Filings
2025-07-09 English
Director's Dealing 2025
Director's Dealing
2025-07-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a description of a transaction clearance under foreign direct investment laws and expected closing dates, but it does not contain financial statements or detailed financial analysis. It is not an annual or quarterly report, nor an earnings release. The document is a regulatory announcement of a material event rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2025-06-26 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 12, 2025, reporting the submission of matters to a vote of security holders at the company's annual general meeting. It includes detailed voting results for director election and ratification of the independent auditor. The content focuses on the official results of shareholder votes at the AGM, which matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4182 characters, which is relatively short but contains substantive voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA). It is not a proxy solicitation or management report but specifically the voting results. Hence, the correct classification is DVA with high confidence.
2025-06-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.